Recurrent Glioblastoma Multiforme Treatment Market Analysis-2027

1. RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Recurrent Glioblastoma Multiform Treatment Market - Overview Recurrent Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027 Glioblastoma Multiforme Treatment Market, by Treatment (Oral Medication, Global Recurrent Glioblastoma Multiforme Treatment Market, by Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 369.6 million in 2020 and is expected to exhibit a CAGR of 6.14% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights. Key players are involved in strategic collaborations to expand their market presence. For instance, in May 2017, DelMar Pharmaceuticals entered into a Sciences, a contract research organization (CRO), to conduct phase III trials of VAL-083 for the treatment of recurrent glioblastoma multiforme. A global leader of CRO, PRA Health Sciences, provides outsourced clinical development services to the biotechnology as well as pharmaceutical industries. collaboration agreement with PRA Health For instance, in January 2020, a bevacizumab biosimilar, Zirabev, was launched by Pfizer in the U.S. for the treatment of recurrent GBM. Browse Research Reports: https://www.coherentmarketinsights.com/market- insight/glioblastoma-multiforme-market-682 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION Recurrent Glioblastoma Multiforme Treatment Market - Impact of Coronavirus (Covid-19) Pandemic The COVID-19 outbreak has immensely affected the recurrent glioblastoma multiforme treatment market growth. According to the Centers for Disease Control and Prevention (CDC), patients aged 65 years & above and those with hysterical comorbidities are considered at high risk of being affected with COVID-19 infection. Therefore, based on these risk factors, it is recommended to the glioblastoma multiforme patients with recurrent GBM to be strongly considered for hypofractionated RT regimens. The recurrent GBM industry is likely to get impacted due to COVID-19 pandemic and the treatments for this disease will evolve in the near future. Browse 26 Market Data Tables and 28 Figures spread through 160 Pages and in-depth TOC on Recurrent Glioblastoma Multiforme Treatment Market, By Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, and Chemotherapy ), by Type (Grade II or Grade III, Grade IV, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Forecast to 2027” Key players in the market are adopting several strategies such as mergers & acquisitions, collaborations, and joint ventures to strengthen their position in the global market. For instance, in October 2019, Advaxix and UCLA entered into a research agreement for the development of GBM immunotherapy products. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/682 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Key Takeaways of the Global Recurrent Glioblastoma Multiforme Treatment Market: The global recurrent glioblastoma multiforme treatment market is expected to exhibit a CAGR of 6.14% during the forecast period (2020-2027), owing to rising prevalence of seizures and the advancements in treatment & partnerships among market players Among type, the grade IV segment accounted for significant revenue share, owing to increasing prevalence of such conditions. For instance, according to the American Association of Neurological Surgeons (AANS), the prevalence of GBM accounts for around 52% of all the primary brain tumors. Major players operating in the global recurrent glioblastoma multiforme treatment market include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc. Boston Biomedical, Inc., Cantex Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/682 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved